Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.79 |
| ▸ | MMP8 | P22894 | 3/20 | 0.79 |
| ▸ | MMP13 | P45452 | 3/20 | 0.79 |
| ▸ | MMP7 | P09237 | 2/20 | 0.79 |
| ▸ | MMP12 | P39900 | 2/20 | 0.79 |
| ▸ | BMP1 | P13497 | 15/20 | 0.65 |
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348032 | 0.81 | BMP1 (0.80) | MMP1MMP8MMP13BMP1MMP2 | |
| SCHEMBL7344309 | 0.81 | BMP1 (0.80) | MMP1MMP8MMP13BMP1MMP2 | |
| SCHEMBL1566873 | 0.78 | MMP13 (1.00) | MMP1MMP8MMP13MMP7MMP12 | |
| SCHEMBL1566475 | 0.78 | MMP13 (1.00) | MMP1MMP8MMP13MMP7MMP12 | |
| SCHEMBL1566876 | 0.78 | MMP13 (1.00) | MMP1MMP8MMP13MMP7MMP12 | |
| SCHEMBL13643229 | 0.76 | MMP9 (0.75) | MMP1MMP8MMP13BMP1MMP2 | |
| SCHEMBL13643228 | 0.76 | MMP9 (0.75) | MMP1MMP8MMP13BMP1MMP2 | |
| SCHEMBL5184099 | 0.76 | MMP1 (0.79) | MMP1MMP8MMP13MMP7MMP12 | |
| SCHEMBL15199461 | 0.75 | MMP2 (0.69) | MMP1MMP8MMP13MMP7MMP12 | |
| SCHEMBL2863211 | 0.74 | BMP1 (0.74) | MMP1MMP8MMP13BMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781601-B1 | DERIVATIVES OF ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID AS MATRIX METALLOPROTEINASES INHIBITORS | PROTERA S R L (IT) | 2010-12-22 | — | — | EP | claimed |
| US-7772430-B2 | Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors | PROTERA S.R.L. (IT) | 2010-08-10 | — | — | US | claimed |
| US-20080249032-A1 | Derivatives of Arylsulfonamido-Substituted Hydroxamic Acid as Matrix Metalloproteinases Inhibitors | PROTERA S.R.L. (IT) | 2008-10-09 | — | — | US | claimed |
| EP-1781601-A2 | DERIVATIVES OF ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID AS MATRIX METALLOPROTEINASES INHIBITORS | Abiogen Pharma S.p.A. (IT) | 2007-05-09 | — | — | EP | claimed |
| WO-2006013193-A2 | DERIVATIVES OF ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID AS MATRIX METALLOPROTEINASES INHIBITORS | ABIOGEN PHARMA S.P.A. (IT) | 2006-02-09 | — | — | WO | claimed |
| EP-2308837-A2 | Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors | Protera S.R.L. (IT) | 2011-04-13 | — | — | EP | disclosed |
| EP-1781601-B1 | DERIVATIVES OF ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID AS MATRIX METALLOPROTEINASES INHIBITORS | PROTERA S R L (IT) | 2010-12-22 | — | — | EP | disclosed |
| US-20100298439-A1 | DERIVATIVES OF ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID AS MATRIX METALLOPROTEINASES INHIBITORS | BERTINI IVANO | 2010-11-25 | — | — | US | disclosed |
| US-7772430-B2 | Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors | PROTERA S.R.L. (IT) | 2010-08-10 | — | — | US | disclosed |
| US-20080249032-A1 | Derivatives of Arylsulfonamido-Substituted Hydroxamic Acid as Matrix Metalloproteinases Inhibitors | PROTERA S.R.L. (IT) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249032-A1 | Derivatives of Arylsulfonamido-Substituted Hydroxamic Acid as Matrix Metalloproteinases Inhibitors | MMP1, MMP15, MMP17 | MMP1 1/4885MMP8 42/4885MMP13 13/4885 |
| US-20100298439-A1 | DERIVATIVES OF ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID AS MATRIX METALLOPROTEINASES INHIBITORS | MMP1, MMP15, MMP17 | MMP1 1/4885MMP8 42/4885MMP13 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.